Peer-reviewed veterinary case report
High aldosterone and eplerenone treatment in cats with kidney disease
By Kai, Michino et al.·Published in The Canadian veterinary journal = La revue veterinaire canadienne·2022·The United Graduate School of Veterinary Science, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effects of plasma aldosterone concentration and treatment with eplerenone on the survival of cats with chronic kidney disease.
- Species:
- cat
Plain-English summary
A group of cats with chronic kidney disease (CKD) had their blood tested for a hormone called aldosterone, which was found to be higher in sick cats compared to healthy ones. Cats with high levels of this hormone had a shorter survival time. However, when these cats were treated with a medication called eplerenone, their survival time improved significantly. This suggests that monitoring aldosterone levels could help predict outcomes in CKD cats, and eplerenone may be a beneficial treatment for those with high levels.
People also search for: cat chronic kidney disease treatment · eplerenone for cats · high aldosterone in cats · cat kidney disease prognosis
Abstract
This study investigated the plasma aldosterone concentration (PAC) in cats with chronic kidney disease (CKD) and retrospectively evaluated the survival of cats with high PAC. Furthermore, this study prospectively examined eplerenone's effect on survival time in CKD cats with high PAC. The PAC was measured retrospectively in blood samples obtained from 156 client-owned cats that visited a veterinary hospital. The cats were designated into 2 groups: clinically healthy (= 101) and those with CKD (= 55). The PAC was measured by solid-phase radioimmunoassay; median (minimum-maximum) PAC in healthy cats was 97 pg/mL (range: 10 to 416 pg/mL) and the upper limit (95th percentile) was 243 pg/mL. In the CKD group, PAC [126 pg/mL (range: 10 to 981 pg/mL)] was higher (< 0.01) than in the clinically healthy group. In cats with CKD, the survival time of those with high PAC (= 16) (> 243 pg/mL) was shorter (= 0.019) than that of those (= 39) with normal PAC. Administering an aldosterone antagonist, eplerenone, at 2.5 to 5 mg/kg body weight prolonged survival (= 0.005) in CKD cats with high PAC (= 8). In conclusion, PAC could be a prognostic marker of CKD in cats and eplerenone may prolong survival in cats with CKD and a high PAC.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/36467377/